All issues
Volume 121 (2003)
- Issue 6 Pages 377-
- Issue 5 Pages 290-
- Issue 4 Pages 203-
- Issue 3 Pages 143-
- Issue 2 Pages 85-
- Issue 1 Pages 4-
Volume 121, Issue 3
Displaying 1-5 of 5 articles from this issue
- |<
- <
- 1
- >
- >|
Award Lecture
-
Katsuhiko MURAKIArticle type: Award Lecture
2003Volume 121Issue 3 Pages 143-151
Published: 2003
Released on J-STAGE: February 25, 2003
JOURNAL FREE ACCESSChanges in intracellular Ca concentration ([Ca2+]i) play dominant roles in the regulation of ion channel activity. Thus, analyses of Ca-related ion channels, whose activation is responsible for and/or dependent on the changes in [Ca2+]i, are important to understand the physiological and pharmacological characteristics of smooth muscle cells (SMCs) and endothelial cells (ECs). We have clarified that, in SMCs, Ca mobilization by membrane depolarization and bioactive substances affects the activity of Ca-activated K (IK-Ca) and Cl channel currents. On the other hand, by measuring IK-Ca as an indicator of Ca mobilization, we found that palmitoylcarnitine (PC), a lipid released under ischemic conditions, mobilizes Ca in ECs via stimulation of endothelial differential gene (Edg) receptors. Moreover, sphingosine-1-phosphate, which is a lipid mediator and has a similar structure to PC, elevated [Ca2+]i in ECs via the activation of cation channels through Edg1 receptors. A myo-endothelial interaction is another regulatory factor of Ca mobilization in ECs as well as in SMCs. Nifedipine and levcromakalim, which have no effects on ion channels in ECs themselves, changed the membrane potential of ECs via a myo-endothelial pathway. These integral analyses provide better understanding of the functional roles of Ca-related ion channels and their involvement in Ca mobilization in SMCs and ECs.
View full abstractDownload PDF (110K) -
Toshimasa ISHIZAKIArticle type: Award Lecture
2003Volume 121Issue 3 Pages 153-162
Published: 2003
Released on J-STAGE: February 25, 2003
JOURNAL FREE ACCESSRho is a member of the Ras-related family of small molecular weight GTP-binding proteins, and Rho works as a molecular switch by shuttling between the GDP-bound inactive form and the GTP-bound active form. Rho is involved in cell motility, cell adhesion, and cytokinesis through the reorganization of the actin cytoskeleton. In addition to this, Rho also regulates Ras-induced transformation, transcriptional activation and cell cycle progression. These actions through the Rho signaling are mediated by downstream Rho effectors. Several putative Rho effectors including ROCK and mDia have been isolated on the basis of their selective binding to the GTP-bound form of Rho. Among them, the ROCK family of Rho-associated serine/threonine protein kinases inactivates myosin phosphatase and actin depolymerizing factor (cofilin/Destrin) to induce stabilization of filamentous actin and increase in the actomyosin-based contractility. mDia binds profilin likely to promote actin polymerization. Thus, these effectors are supposed to work in organization of the actin cytoskeleton. Furthermore, analyses using a ROCK specific inhibitor Y-27632 have suggested that the Rho-ROCK pathway works in contractions of vascular smooth muscles and is involved in malignant cell transformation and tumor invasion and metastasis.
View full abstractDownload PDF (109K) -
Izumi HIDEArticle type: Award Lecture
2003Volume 121Issue 3 Pages 163-173
Published: 2003
Released on J-STAGE: February 25, 2003
JOURNAL FREE ACCESSTumor necrosis factor (TNF) is a potent inflammatory cytokine involved in many pathophysiological conditions including rheumatoid arthritis and Crohn's disease. Despite recent evidence regarding signal transduction via TNF receptor and its biological actions, the mechanism of TNF release remains poorly understood. To clarify how production and release of TNF are regulated, we focused on mast cells and microglia which are involved in allergic inflammation and brain damage or recovery, respectively. In RBL-2H3 mast cells, anti-allergic drugs including azelastine inhibited the release of TNF more potently than degranulation in response to antigen or ionomycin. It was also demonstrated that TNF releasing steps are regulated via the PKCα-dependent pathway. Furthermore, Rho GTPases, possibly Rac, were shown to be involved in antigen-induced TNF transcription through activating PKCβI. In cultured rat brain microglia, we found that extracellular ATP triggers the release of TNF via the P2X7 receptor. ERK and JNK are also involved in ATP-induced TNF transcription, while p38 regulates the transport of TNF mRNA from the nucleus to the cytosol. Additionally, JNK and p38, but not ERK, are activated via the P2X7 receptor. A better understanding of the specific pathways that regulate TNF release for each effector cell may offer further possible therapeutic targets for inflammatory diseases.
View full abstractDownload PDF (446K)
Technical Note
-
Toshihiko MomiyamaArticle type: Technical Note
2003Volume 121Issue 3 Pages 174-180
Published: 2003
Released on J-STAGE: February 25, 2003
JOURNAL FREE ACCESSMore than ten years have passed since the slice-patch-clamp technique was established as a powerful method for the analysis of central synaptic transmission. Although this technique was restricted only to young animal preparations, we can now apply it to several synapses in slices obtained from adult animals, owing to recent advances in optics or slicers. In addition, advanced techniques have been recently available such as paired whole-cell recording from two or more synaptically connected neurons, recording from dendrites or some presynaptic terminals. Further developments are expected in both of the two directions: more microscopic analysis such as investigating glutamatergic sensitivities of single dendritic spines in combination with two-photon photolysis of a caged-glutamate compound and analysis in a more physiological function-oriented manner such as investigation of pain perception mechanisms using in vivo patch-clamp technique.
View full abstractDownload PDF (78K) -
Hideo SAJI, Yasuhiko IIDAArticle type: Technical Note
2003Volume 121Issue 3 Pages 181-191
Published: 2003
Released on J-STAGE: February 25, 2003
JOURNAL FREE ACCESSThe nuclear imaging technologies, positron emission tomography (PET) and single photon emission computed tomography (SPECT), have the power to non-invasively obtain dynamic and real-time information on the in vivo behaviors of radiolabeled molecules not only in humans but also in experimental animals. Thus, PET and SPECT can image molecular interactions of biological processes in vivo directly and reveal biological phenomena that are hidden from view. Furthermore, these imaging procedures also can be repeatedly performed before and after interventions, thereby allowing each subject to be used as its own control. In these studies, the radiolabeled compounds used as imaging probes for non-invasive assays of biochemical processes should have defined in vivo behaviors that can provide valuable information on the physiological and pharmacological processes. This paper describes the principle of the nuclear medical imaging systems, rational design of radiolabeled imaging probes, and the application to in vivo investigation of the change of various neurotransmission systems under disease and drug treatment. The efficient utilization of these nuclear medical imaging technologies will accelerate biomedical studies and drug development.
View full abstractDownload PDF (157K)
- |<
- <
- 1
- >
- >|